Compare Arm Holdings plc (ARM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs Zoetis Inc — how do they compare? Arm Holdings plc trades at $313.01 (market cap $345.41B), while Zoetis Inc trades at $75.97 (market cap $31.68B). The key difference: Arm Holdings plc is far larger — about 10.9× Zoetis Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Arm Holdings plc pays none. Which is the better fit depends on your goals.
| ARM | ZTS | |
|---|---|---|
Market Cap | $345.41B | $31.68B |
Sector | Technology | Health |
52-Week High | $439.46 | $156.76 |
52-Week Low | $104.55 | $71.91 |
Enterprise Value | $342.26B | $38.97B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
Zoetis (ZTS) trades at $75.56, up 0.64% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 28.03% net margins and 67.75% ROE, supported by consistent revenue growth to $9.47B in 2025. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with a $101.43 price target. Legal developments include multiple securities class action notices with July 27, 2026 deadlines.
ZTS presents a mixed outlook with strong fundamental performance offset by technical weakness and legal overhangs. The stock trades at attractive valuations (P/E 12.39) with significant upside to analyst targets, but investors face near-term volatility from the class action proceedings and recent earnings miss. Long-term growth prospects remain solid given the company's market leadership in animal health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
